UnknownPHASE2, PHASE3NCT03624530

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanfang Hospital, Southern Medical University
Principal Investigator
Qifa Liu
Nanfang Hospital, Southern Medical University
Intervention
Tyrosine kinase inhibitor (TKIs)(drug)
Enrollment
82 enrolled
Eligibility
14-65 years · All sexes
Timeline
20182022

Study locations (1)

Collaborators

Peking University People's Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou First People's Hospital · Zhujiang Hospital · Third Affiliated Hospital, Sun Yat-Sen University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03624530 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials